Free tool
FAERS Monitor: Advil Allergy Sinus
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021441 or its brand name (Advil Allergy Sinus, Chlorpheniramine Maleate, Ibuprofen, Pseudoephedrine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
237
Serious
31
13% of reports
Hospitalization
3
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective79
- product use in unapproved indication30
- drug effective for unapproved indication23
- drug effect incomplete13
- dizziness10
- somnolence9
- headache8
- insomnia8
- therapeutic response unexpected8
- nausea7
- feeling abnormal6
- drug ineffective for unapproved indication5
- therapeutic product effect incomplete5
- urticaria5
- condition aggravated4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 23 |
| 2012 | 9 |
| 2013 | 13 |
| 2014 | 16 |
| 2015 | 28 |
| 2016 | 16 |
| 2017 | 6 |
| 2018 | 14 |
| 2019 | 7 |
| 2020 | 7 |
| 2021 | 33 |
| 2022 | 8 |
| 2023 | 10 |
| 2024 | 11 |
| 2025 | 13 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug effective for unapproved indicationSignal | 23 | 69.7 | 47.3 | 1,491 |
| drug effect incompleteSignal | 13 | 31.8 | 18.7 | 358 |
| therapeutic response unexpectedSignal | 8 | 15.8 | 8.0 | 97 |
| product use in unapproved indicationSignal | 30 | 10.7 | 7.7 | 258 |
| drug ineffective for unapproved indicationSignal | 5 | 8.1 | 3.4 | 24 |
| therapeutic product effect incompleteSignal | 5 | 6.2 | 2.6 | 17 |
| drug ineffectiveSignal | 79 | 5.3 | 4.4 | 291 |
| somnolenceSignal | 9 | 4.0 | 2.1 | 17 |
| insomniaSignal | 8 | 2.7 | 1.3 | 7 |
| urticaria | 5 | 2.6 | 1.1 | 4 |
| feeling abnormal | 6 | 2.2 | 1.0 | 3 |
| dizziness | 10 | 1.8 | 1.0 | 3 |
| condition aggravated | 4 | 1.2 | 0.4 | 0 |
| headache | 8 | 1.1 | 0.6 | 0 |
| nausea | 7 | 0.8 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.